Perrigo Company (NYSE:PRGO) EVP Sharon Kochan sold 318 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $81.36, for a total transaction of $25,872.48. Following the transaction, the executive vice president now owns 10,231 shares in the company, valued at $832,394.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Sharon Kochan also recently made the following trade(s):
- On Thursday, August 31st, Sharon Kochan sold 1,500 shares of Perrigo stock. The stock was sold at an average price of $79.03, for a total transaction of $118,545.00.
Perrigo Company (PRGO) traded up 2.75% on Monday, reaching $85.07. 1,932,496 shares of the company’s stock traded hands. The stock has a 50-day moving average of $75.90 and a 200 day moving average of $72.95. The firm’s market capitalization is $12.13 billion. Perrigo Company has a 52 week low of $63.68 and a 52 week high of $99.14.
Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Thursday, August 10th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.28. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.18 billion. Perrigo had a negative net margin of 51.04% and a positive return on equity of 11.55%. The business’s quarterly revenue was down 7.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.93 earnings per share. On average, equities analysts expect that Perrigo Company will post $4.58 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Friday, August 25th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Wednesday, August 23rd. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.75%. Perrigo’s dividend payout ratio is currently -3.51%.
Institutional investors and hedge funds have recently bought and sold shares of the company. Credit Suisse AG raised its stake in shares of Perrigo by 13.8% during the first quarter. Credit Suisse AG now owns 241,688 shares of the company’s stock valued at $16,046,000 after purchasing an additional 29,375 shares during the period. Allen Investment Management LLC grew its position in shares of Perrigo by 7.1% during the second quarter. Allen Investment Management LLC now owns 7,143 shares of the company’s stock worth $539,000 after buying an additional 473 shares in the last quarter. Amalgamated Bank grew its position in shares of Perrigo by 6.0% during the first quarter. Amalgamated Bank now owns 9,759 shares of the company’s stock worth $648,000 after buying an additional 555 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its position in shares of Perrigo by 32.5% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 54,530 shares of the company’s stock worth $4,118,000 after buying an additional 13,382 shares in the last quarter. Finally, LMR Partners LLP acquired a new stake in shares of Perrigo during the second quarter worth approximately $290,000. Institutional investors own 80.36% of the company’s stock.
A number of equities analysts recently weighed in on the stock. BidaskClub upgraded shares of Perrigo from a “strong sell” rating to a “sell” rating in a research report on Saturday. Jefferies Group LLC reaffirmed a “hold” rating and set a $71.00 target price (up from $69.00) on shares of Perrigo in a research note on Friday, August 11th. Stifel Nicolaus reaffirmed a “hold” rating on shares of Perrigo in a research note on Friday, August 11th. Oppenheimer Holdings, Inc. assumed coverage on shares of Perrigo in a research note on Thursday. They set an “outperform” rating and a $88.00 target price on the stock. Finally, CIBC assumed coverage on shares of Perrigo in a research note on Thursday. They set an “outperform” rating and a $88.00 target price on the stock. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the company. Perrigo presently has an average rating of “Hold” and a consensus target price of $87.00.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with MarketBeat.com's FREE daily email newsletter.